Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086890 · ClinicalTrials.gov registry record · NA
Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa
A NA study of Retinitis Pigmentosa, sponsored by Nova Southeastern University.
- Active
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02086890: Active NA study of Retinitis Pigmentosa, sponsored by Nova Southeastern University.
NCT02086890 is a NA study of Retinitis Pigmentosa that is active but no longer recruiting, run by Nova Southeastern University. The registered enrollment target is 21 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02086890, a NA study of Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Nova Southeastern University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.
Primary Outcome
Using Haig-Streit Octopus perimeter
Conditions Studied
Interventions
- DEVICE Electro-acupuncture
- DEVICE Laser Acupuncture
- DEVICE Transcorneal Electrical Stimulation
- DEVICE Sham Electro-acupuncture
- DEVICE Sham laser acupuncture
Study Locations (1)
Florida
- Nova Southeastern University; College of Optometry - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT02086890 still lists
NCT02086890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 5 interventions - of which Electro-acupuncture is the first listed.
NCT02086890 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02086890 about?
NCT02086890 is a clinical study titled "Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa". Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.
What is the current status of trial NCT02086890?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2014-08-13. Estimated completion is 2027-12.
What conditions does trial NCT02086890 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT02086890?
The interventions under investigation include: Electro-acupuncture (DEVICE), Laser Acupuncture (DEVICE), Transcorneal Electrical Stimulation (DEVICE), Sham Electro-acupuncture (DEVICE), Sham laser acupuncture (DEVICE).
Who is sponsoring clinical trial NCT02086890?
This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02086890 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02086890's enrollment target sits among peer trials
21 25th of 37 higher than 13 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Experimental and Clinical Studies of Retinal Stimulation
RECRUITING · NA
-
Prospective Natural History Study of Retinitis Pigmentosa
ACTIVE NOT RECRUITING · NA
-
Argus II/ORCAM Device Study
COMPLETED · NA
-
Object Finder for a Retinal Prosthesis
COMPLETED · NA
-
Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI